Main Street Group LTD Sells 476 Shares of Pfizer Inc. (NYSE:PFE)

Main Street Group LTD cut its stake in Pfizer Inc. (NYSE:PFE) by 32.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 982 shares of the biopharmaceutical company’s stock after selling 476 shares during the period. Main Street Group LTD’s holdings in Pfizer were worth $26,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $27,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $28,000. Finally, Noble Wealth Management PBC acquired a new position in shares of Pfizer in the fourth quarter valued at $31,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.0%

Shares of PFE opened at $22.86 on Wednesday. The company has a market capitalization of $129.97 billion, a P/E ratio of 16.21, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The business’s 50 day simple moving average is $23.89 and its 200-day simple moving average is $25.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm earned $0.82 earnings per share. The business’s revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.52%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Finally, Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.